NKTR share price trailing 3-Y Beta is 3.04, making a possible higher RoR yet also presenting more risk. Profit to share is at $3.96 over last 12 months. Shares increased 26.32 (%) (YTD) for a decline of -40.58 (%) over the last twelve months. Stock prices are -62.72 (%) from year high of $111.36 and 42.09 with the 52 Week lowest stock price at $29.22. Overall the stocks consensus estimates are 1.8 – out of 5, stock experts rate these shares a buy.
Nektar Therapeutics (NKTR) could see increases of 90 (%) within the next year to $125price as 12-month high target. For a 201.06 (%) increase compared to the stocks current price. The 12-month median targeted valuation forecasted price by stock experts is $73, possible return at 75.82 (%) as share prices closed at $41.52 on Monday, January 14. The bottom estimated targeted valuation for shares are $34 an increase upwards of -18.11 (%) than NKTR’s stock price today.
Stocks for Nektar Therapeutics decreased due to 21 earnings reactions and increasing 0.06 (%) on earnings reports.
In Nektar Therapeutics (NASDAQ:NKTR) we see trading started at 11/16/2018. Doberstein Stephen K decided to sell 4.52 thousand of this stock priced $38.25. For a value of $173.04 thousand. Following the transaction, the SVice President & Chief Scientific Officer was at 78.73 thousand of this stock. Share price increased 7.22 (%) post-sale. Then at 11/16/2018, Hora Maninder, SVice President Pharma Dev & Mfg Ops, sold 4.69 thousand of this stock at a share price of $38.25. Taking out 179.55 thousand of this stock from the directors portfolio and shares hit a 7.22 (%) rally in value since the news became public. 81.03 thousand of this stock in the SVice President Pharma Dev & Mfg Ops account.
On 11/16/2018, SVice President & Chief Financial Officer Labrucherie Gil M decided to sell stock of $249.2 thousand. Selling at $38.25 reducing 6.52 thousand of this stock from their trading account. Then shares made a 7.22 (%) gains after the stock purchase. They now have 106.54 thousand of this stock left in their portfolio. Nicholson John, who performs the SVice President & Chief Operating Officer job, sold 5.98 thousand of this stock for $228.81 thousand. They sold on the 11/16/2018 at an averaged $38.25 share price. Stock prices then soared 7.22 (%). Nicholson John has now 174.48 thousand NKTR shares in the company at $7.24 million following the sale.
The Company’s stock prices are at $40.52. With support at $39.53. Up to now NKTR shares trade higher than this price, investors are OK for now. RSI went to 64.8 which is not good. If prices go to below $39.53 more sell-offs are forecasted. However if shares go to $42.2 then we could see trading at a $42.89 price.
Company stock of Nektar Therapeutics (NKTR) have Profit-Earnings Ratio at 9.56 (x) 12 month earnings reports. This market NKTR is in has a median Profit-Earnings Ratio at 95.96. The Profit-Earnings Ratio dipped to 61.49X while rising to 61.49 in charts over last 5 years and is at 5.82 P/S ratio. Price-to-Sales ratio at 242.95. 97.9 (%) GPM for Nektar Therapeutics with OPM currently at 61.2 (%). NPM is 59.7 (%).